# 12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.

> **NCT00735007** · PHASE3 · COMPLETED · sponsor: **EMD Serono** · enrollment: 106 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Rebif® New Formulation (RNF) using RebiSmartTM

## Key facts

- **NCT ID:** NCT00735007
- **Lead sponsor:** EMD Serono
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2009-01
- **Final completion:** —
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2013-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00735007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00735007, "12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00735007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*